Abstract
A preliminary study of the response of various inoperable malignant diseases to simultaneously administered 5-fluoro-uracil and orthovolt x-ray was performed. The 5-fluoro-uracil was given intravenously at a relatively nontoxic dosage level. The x-ray tumor dose was limited to 2,000 roentgens in every patient.
Pronounced and rapid tumor regression occurred in 12 of 18 evaluable patients. Significant objective response was obtained in each of eight patients with epidermoid carcinoma of the lung.
Toxicity occurred in half of the patients, manifested by pharyngitis, esophagitis, proctitis, leukopenia and thrombocytopenia.
Full text
PDF
Images in this article
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- ANSFIELD F. J., CURRERI A. R. Further clinical studies with 5-fluorouracil. J Natl Cancer Inst. 1959 Mar;22(3):497–507. [PubMed] [Google Scholar]
- CURRERI A. R., ANSFIELD F. J., McIVER F. A., WAISMAN H. A., HEIDELBERGER C. Clinical studies with 5-fluorouracil. Cancer Res. 1958 May;18(4):478–484. [PubMed] [Google Scholar]
- HEIDELBERGER C., CHAUDHURI N. K., DANNEBERG P., MOOREN D., GRIESBACH L., DUSCHINSKY R., SCHNITZER R. J., PLEVEN E., SCHEINER J. Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature. 1957 Mar 30;179(4561):663–666. doi: 10.1038/179663a0. [DOI] [PubMed] [Google Scholar]